Access to capital is often considered primary challenge preventing Maryland from being the top-ranked state for biotech.

The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a biomanufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, Proof of Concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology.

Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million Series C financing.

Leading scientists, public policy experts, and biotech industry leaders joined forces today to launch "Working to Fight AMR," a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance. Working to Fight AMR will also advocate for policies that catalyze the creation of new medicines.

This article is the second in a 4-part series. Part 1 offered background on innovation districts—what they are, where they’re located, how colleges and universities relate, how P3s relate, etc. Part 3 will look at why schools might want to and might not want to consider pursuing an innovation district. Part 4 will feature an interview with Dr. Jane Talkington, scholar of innovation districts for higher ed. 

What is the difference between research parks and innovation districts?

Darmody: The terms are somewhat interchangeable, but essentially, innovation districts generally are more urban in nature with mixed-use amenities, whereas traditional research parks grew up around universities and are in rural, suburban, and urban areas, such as Boston and Austin, but also Lincoln, Nebraska, and Champaign, Illinois. When it comes down to it, though, they share a base concept: Schools and other anchor institutions are trying to build space-placed entities, and corporations come to the university for things like talent.

The record-high surge of initial public offerings (IPOs) in biopharma last year was especially good news for CEOs of many of those newly public companies.

A legal services company and a network analytics firm have been selected as the two latest participants in the Virginia Beach Entrepreneur-in-Residence program, economic development officials announced Aug. 5.

Treat yourself is a movement among millennials. But it's something that literally any age group can enjoy. These days with so much negative news, Americans are proactively looking for moments of happiness to boost their moods.

Whether you're getting a mani-pedi, playing your favorite mobile games, lounging at the pool, or visiting your favorite restaurant, there’s positive health benefits associated with giving yourself a bit of “me time.”

The mobile gaming experts at Fort Mason Games— the female run mobile gaming company that creates games designed to help people relax, destress, and socialize— know how important it is to do something nice for yourself once in a while.

That's why they commissioned a national survey to find out what Americans think about these occasional respites from routine. Mobile gaming is just one of the ways people choose to treat themselves regularly, taking time to do something special just for themselves!

Here’s some of the ways Americans treat themselves:

WASHINGTON, COLORADO, MARYLAND ARE THE TOP 3 INDULGING STATES. With 93% of Washingtonians (the state, not the district) saying they treat themselves the most, it tops the list-- though Colorado (91%) and Maryland (90%) are hot on their heels.

Kolaleh Eskandanian, PhD, is the vice president and chief innovation officer of Children's National Health System in Washington, D.C.

Here, Dr. Eskandanian outlines the big cybersecurity challenges and how she expects her role as the chief innovation officer at Children's National to evolve over the next few years.

This round nearly doubles the Sterling company’s funding raised to date.

Thursday marks the grand opening of Mayo Clinic’s new Discovery and Innovation Building, home to a pioneering technology that will increase the number of lungs available for transplant as well as a new hub for Northeast Florida’s entrepreneurs to get together, share ideas, develop new products and services, and create new companies.

The National Institutes of Health's National Cancer Institute has awarded an international group led by Johns Hopkins University researchers a $940,000 grant to study extracellular vesicles (EVs) that can be used to diagnose disease, track disease status, and potentially deliver therapies.

The company plans to double its employee count in the next two years.

The future of healthcare is precision medicine—with the potential to revolutionise healthcare and move from a one-size-fits-all approach to an individualised one, precision medicine is viewed as an emblem of a new age. 

LSIPR has discovered the top things you must consider when looking to protect your inventions in the US and/or Europe, plus one issue which matters wherever you are in the world.

Healthcare analytics compliance company Protenus raised $17 million in new funding, its leadership announced this week.

The Series C round was led by LTP, which focuses on investments in health IT and services companies. Also participating in the round were Kaiser Permanente Ventures, F-Prime Capital, Arthur Ventures, Lionbird and Providence Ventures.

Maryland's flagship university hopes to forge ties with HQ2.

REGISTER NOW FOR OUR GREATLY ANTICIPATED 4TH ANNUAL REGIONAL CONFERENCE SEPTEMBER 19, 2019

Inova Center for Personalized Health, Fairfax You’re invited to spend the day with innovative entrepreneurs, professionals and industry leaders. Discover opportunities to help you navigate through a rapidly evolving modern industry & gain access to cutting edge technologies and tools.

With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on the hunt for a new manufacturing site to fuel those hopes. The company found it in Maryland.

REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.

Shipping containers are continuing to prove their worth outside of transportation. From serving as a community-connecting space to an urban farm, one organization is now bringing them into education as mobile laboratories.

George Washington University just sold a portion of its royalty rights for a drug developed in its school of medicine, scoring a game-changing cash infusion it plans to reinvest in research and commercialization.

Through gene analysis, researchers have found different types of interferons in systemic lupus erythematosus (SLE) tissues and cells, such as skin and synovium. The analysis, which probed 2,000 gene expression datasets from SLE patients, specifically investigated modules of genes derived from the downstream interferon gene signature. It found enriched downstream interferon signatures that were predominately from IFNB1. These interferon signatures were higher when compared with the expression of downstream interferon signatures in kidneys with lupus nephritis, according to the study, published April 23 in Nature Communications Biology.1

Targeting Metabesity 2019, co-chaired by Kinexum Executive Chairman Zan Fleming and Stanford Professor Larry Steinman (a co-discoverer of Tysabri), will take place October 15-16, 2019, at the Carnegie Institution for Science in Washington, DC, see https://www.linkedin.com/pulse/targeting-metabesity-2019-thomas-seoh/.

Emerging science over the past couple decades suggests that many chronic diseases of aging (including diabetes, obesity, cardiovascular and neurodegenerative diseases, cancer and the aging process itself) have common metabolic roots, and thus may be susceptible to common solutions. We believe we are at a similar stage to the cusp of the moonshot, or the human genome project, where the science is accumulating, but alignment of policy and socioeconomic factors may be needed, in order to enable and facilitate the translation of such science into material, accessible gains in public health.

Perhaps the report on China’s strategy for eclipsing the U.S. lead in biopharma from the Information Technology & Innovation Foundation (ITIF) resonated so strongly with me because of several articles in The Wall Street Journal. Taken together, they present a sobering picture of what we’re up against.

EDA is encouraging its economic development partners to think of Opportunity Zone investment as a new arrow in their quiver to not only enhance ROI for business interests, but also to encourage the public/private partnerships needed to drive private investment to distressed areas.

Bayer made much of its desire to establish a cell therapy pipeline on August 8 when it announced it would shell out up to $600 million to acquire full control of BlueRock Therapeutics. But the deal is just the latest example of growing interest by biopharma giants in applying gene editing toward new treatments.

Floreo started raising capital earlier this year to get its product in the hands of more users.

Institute for Bioscience and Biotechnology Research (IBBR) Fellow Dr. Daniel Nelson (Associate Professor, Department of Veterinary Medicine, University of Maryland, College Park) is working on an innovative approach to treating bacterial disease in collaboration with Dr. Rajan Adhikari, Assistant Director of Bacteriology at Integrated BioTherapeutics (IBT), and George Mason University's Dr. Ramin Hakami (Associate Professor, School of Systems Biology and National Center for Biodefense and Infectious Diseases). The group recently received a $3M Phase II STTR award from the National Institutes of Health that will fund advancement of their novel immunotherapeutic into non-human primates, as well as optimization of a cell line for biomanufacturing the drug.

A US/Ko re an hy brid biotech run by a group of sci en tists out of Johns Hop kins just scored a megaround of $137.1 mil lion, with plans to ad vance a slate of ex per i men tal drugs held at its 3 sub sidiary op er a tions.

The state-backed tech group is also in the midst of finding a new CEO to replace George Davis, who left in July.

Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care. The challenge, “Transforming IBD Care: Better disease monitoring, management, and care for people with inflammatory bowel disease” focuses on innovation in IBD monitoring, condition management or care enhancements.

Virginia Bio, the statewide non-profit trade association for the life science industry, today announces that John L. Newby II is named CEO, effective August 5, 2019.

Tweet this Newby will be leaving his current role as the Commissioner of the Virginia Department of Veterans Services (VDVS), where he leads an 850-member Agency located across 50 Virginia locations, delivering employment, education, benefits, behavioral health and long term health care services to Virginia’s Reservists, Guardsmen, transitioning service members and 725,000 veterans.

Three health care-related startups based in the Richmond area have merged their operations with the goal of providing better preventative and personalized medical diagnostics.

The merger brings together Salveo Diagnostics, ImmunArray and Nudge, in what leaders of the three businesses describe as a combination “greater than the sum of its parts.”

7th Annual Pediatric Device Innovation Symposium | Pediatric Device Clinical Trials: Forging a Better Path

On September 22, 2019, one day before The MedTech Conference powered by AdvaMed, join stakeholders from the industry, government, academia and patient groups for the nation’s leading pediatric innovation symposium where we will focus on unique challenges and opportunities related to pediatric device trials. Now in its seventh year, the one-day symposium, hosted by Children’s National Health System, brings together key leaders in the device space to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere. Another highlight is the 'Make Your Medical Device Pitch for Kids' competition.